---
title: 'Senior Computational Biologist – Early Discovery Immunology at Recursion'
canonical: 'https://feeny.ai/job/senior-computational-biologist-early-discovery-immunology-recursion-new-york-wjbrcxg1a0ze'
type: 'job'
last_seen: '2026-09-08'
---

# Senior Computational Biologist – Early Discovery Immunology at Recursion

- **Company:** Recursion
- **Location:** New York, NY / Salt Lake City, UT
- **Posted:** 2026-07-09
- **Last confirmed live:** 2026-09-08
- **Apply:** https://job-boards.greenhouse.io/recursionpharmaceuticals/jobs/8054379

## Job description

Your work will change lives. Including your own.

The Impact You’ll Make

As a computational biologist within Recursion’s early discovery team, you will be at the forefront of reimagining drug discovery from first principles. Your mission is to integrate Recursion’s massive datasets—phenomics, transcriptomics, genomics, proteomics—to nominate novel targets, validate disease biology, and define the precision I&I strategies to advance our most promising therapeutic targets into full-fledged drug discovery programs.

This is a highly collaborative role: you will partner with biologists, chemists, data scientists, platform and data engineers, and translational experts to develop and scale methods for target discovery and validation. You will also partner with computational scientists from across the organization to develop novel approaches to agentic target packages, early translational de-risking, and mechanism of action identification. The ideal candidate has strong stakeholder management, technical communication skills, and 3+ years biotech or pharma experience in early drug discovery.

We are hiring for two roles on a new target ID team, one domain expert in immunology and inflammatory diseases (this role) and one in precision oncology.

In this role, you will:

- Drive Target Discovery: Evaluate the molecular evidence for target nomination and validation, leveraging Recursion’s platform to identify novel vulnerabilities in I&I disease biology
- Pilot novel methods for target discovery, disease biology validation, and early patient population hypotheses to send programs into nomination cascades
- Define internal criteria for target data packages and early patient population strategy
- Connect your innovative analysis methods to platform and engineering teams so that we solve the current project and accelerate future ones
- Collaborate cross-functionally: Partner with biologists, medicinal chemists, translational, and portfolio leads to build compelling data packages that drive program milestones and internal investment decisions.
- Present data analysis to decision makers and stakeholders in a clear and compelling way that drives toward getting medicines to patients.

The Team You’ll Join

Our group is a bold, agile, diverse collective of computational drug discovery scientists deeply focused on the singular goal of bringing new therapeutics into the clinic at an accelerated pace. Our expertise spans precision oncology, I&I (immunology and inflammation), and neuroscience and we focus on advancing novel, targeted therapies in these disease areas. We partner closely with other functions to design and execute impactful and decisional data analyses for new targets and drug programs and are responsible for data strategy across the portfolio. We prioritize career development, fluency at the intersection of biology and technology, and a strong network of technical feedback and support.

The Experience You’ll Need

- PhD in a relevant field (computational biology, bioinformatics, systems biology, immunology, etc.) with a very strong computational focus and 3+ years of experience in biotech or pharma industry OR MS in a relevant field and 5+ years of experience in biotech or pharma industry solving fundamental problems in early drug discovery
- Domain expertise in immunological diseases and target id
- Strong understanding of patient genetics and druggability of disease relevant pathways
- Experience applying computational methods (including probabilistic, statistical, and/or machine learning techniques) to analyze and integrate complex biological and/or human clinical data in a high level programming language such as Python or R
- Exceptional data visualization skills
- Excellent cross-functional communication skills, including an ability to explain complex scientific concepts to a variety of audiences using a combination of plots, documents, and presentations

Nice To Have:

- Experience building a target discovery engine using public and proprietary datasets
- Experience designing high-throughput screens with CRISPR or small molecule perturbations to validate therapeutic hypotheses
- Previous exposure to efficient drug program advancement from proof of concept to IND

Working Location & Compensation:

This is an office-based, hybrid role in our Salt Lake City, UT or New York, NY offices. Employees are expected to work in the office at least 50% of the time.

At Recursion, we believe that every employee should be compensated fairly. Based on the skills, experience, and qualifications needed for this role, the estimated annual base salary range is:

- New York City: $166,980 to $220,660
- Salt Lake City: $151,800 to $200,600

In addition to base salary, this role is eligible for an annual bonus, equity compensation, and a comprehensive benefits package.

## #LI-EP1

The Values We Hope You Share:

- We act boldly with integrity. We are unconstrained in our thinking, take calculated risks, and push boundaries, but never at the expense of ethics, science, or trust.
- We care deeply and engage directly. Caring means holding a deep sense of responsibility and respect - showing up, speaking honestly, and taking action.
- We learn actively and adapt rapidly. Progress comes from doing. We experiment, test, and refine, embracing iteration over perfection.
- We move with urgency because patients are waiting. Speed isn’t about rushing but about moving the needle every day.
- We take ownership and accountability. Through ownership and accountability, we enable trust and autonomy—leaders take accountability for decisive action, and teams own outcomes together.
- We are One Recursion. True cross-functional collaboration is about trust, clarity, humility, and impact. Through sharing, we can be greater than the sum of our individual capabilities.

Our values underpin the employee experience at Recursion. They are the character and personality of the company demonstrated through how we communicate, support one another, spend our time, make decisions, and celebrate collectively.

More About Recursion

Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncology, rare disease, neuroscience, immunology, and other therapeutic areas with significant unmet need. Enabling its mission is the Recursion OS, an AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system. Powered by proprietary multimodal data, purpose-built AI models, and bilingual teams fluent in both science and AI, the Recursion OS is designed to translate complex science into medicines that matter — faster, better, and at scale — for patients who are waiting.

Recursion’s platform infrastructure is anchored in Salt Lake City, Utah and Milton Park, Oxfordshire, where its automated biology and chemistry laboratories generate proprietary data at industrial scale. Recursion also maintains offices in New York, Montréal, and London, three global hubs for talent and leadership at the intersection of AI and scientific innovation. Learn more at [www.recursion.com](https://www.globenewswire.com/Tracker?data=RX8_3OmD5YHn9KPS0dIZWI5SJTXw7o78IX71mdHWAptB3UnjQ7VNutoXIyTbG5D_sBzYYsRPGsSI2UDwEODguVwc0tsA_7kbn2hIXe7Xb8g=), or connect on [X](https://www.globenewswire.com/Tracker?data=PEN8v5P4NfB9Je1Ehd4M665lSNOQWhGtMQkvFASBLBI-jFZV3X4qcj21uQ1akOvCKbQGxe8fC1gw7KzH_yFxhw==) and [LinkedIn](https://www.globenewswire.com/Tracker?data=NZ3-__S7n3thuUCJDwe4LbKB3mL3beP5InfKrkM-PaMYe7yHWExchDgzH5kpuanTnSQt567E9X4FJ-sc4RRSbXAPzNGE7JsoG7bLhL2f84LlAk2rLmDecui7soYSVpUY).

Recursion is an Equal Opportunity Employer.  All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, disability, veteran status, or any other characteristic protected under applicable federal, state, local, or provincial human rights legislation.

Accommodations are available on request for candidates taking part in all aspects of the selection process.

Recursion leverages AI in our hiring process. We use Greenhouse's Talent Matching AI technology feature to help review applications against the skills and experience we've identified as important for this role. It analyzes your resume and application responses to assess how closely your qualifications match our criteria - but all decisions are made by our human recruiters and hiring managers, including whether to move to the next phase of review. Talent Matching does not automatically advance or reject any candidate. By submitting your application, you acknowledge that you have been informed about and consent to this use of the Talent Matching tool in our review process. Please refer to our Recursion Privacy Policy at https://www.recursion.com/privacy-notice/ for more information about our processing of personal data and your rights.

Recruitment & Staffing Agencies: Recursion Pharmaceuticals and its affiliate companies do not accept resumes from any source other than candidates. The submission of resumes by recruitment or staffing agencies to Recursion or its employees is strictly prohibited unless contacted directly by Recursion’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of Recursion, and Recursion will not owe any referral or other fees. Our team will communicate directly with candidates who are not represented by an agent or intermediary unless otherwise agreed to prior to interviewing for the job.

## About Recursion

## Company Overview
- **One-liner**: Recursion is a clinical-stage TechBio company that uses artificial intelligence and an industrialized platform to decode biology and industrialize drug discovery.
- **Entity Type**: Public (NASDAQ: $RXRX)
- **Headquarters**: Salt Lake City, Utah, USA
- **Founded**: November 5, 2013
- **Founders**: Blake Borgeson, Ph.D., Chris Gibson, Ph.D., and Dean Li, M.D., Ph.D.

## Core Business
- **Primary industry**: TechBio – AI-powered drug discovery and development (oncology, rare disease, neuroscience, immunology, and other therapeutic areas with high unmet need).
- **Target customers**: B2B (therapeutic partners: Bayer, Roche/Genentech, Sanofi, Merck KGaA, Gates Foundation) and ultimately patients awaiting new medicines.
- **Mission**: “To decode biology to radically improve lives.”

## Products & Services
- **Recursion OS (Recursion Operating System)**: An AI-native, end-to-end drug discovery and development platform that integrates biology, chemistry, and clinical development. It combines massive proprietary multimodal data, purpose-built AI/ML models, and automated wet-lab robotics (including computer vision for phenomics, transcriptomics, proteomics, ADME) to accelerate hit identification to IND-enabling studies up to 3× faster than traditional averages.
- **Clinical-Stage Pipeline** (5 programs):
  - **REC-617**: CDK7 inhibitor for advanced solid tumors.
  - **REC-1245**: RBM39 degrader for biomarker-enriched solid tumors and lymphoma.
  - **REC-3565**: MALT1 inhibitor for hematology indications.
  - **REC-4539**: LSD1 inhibitor for solid tumors and hematology.
  - **REC-4881**: MEK1/2 inhibitor for familial adenomatous polyposis (FAP) – Fast Track designation granted.
- **Open-Source Data & Models**: Non-commercial releases of datasets (e.g., Rxrx1-3), OpenPhenom-S/16 foundation model (on Google Cloud & HuggingFace), and the Boltz-2 model (in collaboration with MIT) for binding affinity prediction – >1,000× faster than traditional physics-based methods.

## Market Standing
- **Valuation/Market Cap**: Not publicly available from provided sources. (As a public company, latest market cap can be found on financial platforms.)
- **Key Metric**: Annual Revenue not disclosed; total funding after IPO not detailed, but the company went public in April 2021 (NASDAQ: RXRX). The latest data highlights >50 petabytes of proprietary data and BioHive-2 supercomputer.
- **Notable Investors/Partners**:
  - **Therapeutic Partners**: Bayer Pharmaceuticals, Roche & Genentech, Sanofi, Merck KGaA (Darmstadt, Germany), The Gates Foundation.
  - **Data & Technology Partners**: NVIDIA, Google Cloud, Helix, Tempus.
- **Growth Signals**:
  - Completed BioHive-2 (most powerful supercomputer wholly owned by any biopharma company, built with NVIDIA).
  - New CEO: Najat Khan, Ph.D. (as of 2025); co-founder Chris Gibson became Chairman.
  - Fast Track designation for REC-4881 (FAP); multiple investigational new drug (IND) applications granted.
  - Expanded London office (King’s Cross) and presence in Toronto (MILA) and Montreal.
  - Open-sourced Boltz-2 (2025) and SynFlowNet-Boltz trainer.

## Competitive Advantages
- **Industrialized End-to-End Platform**: Unlike single-point-solution competitors, Recursion combines automated wet-lab, massive proprietary datasets (>50 petabytes), AI/ML models, and clinical data into a unified “World Model” that continuously improves.
- **Massive Compute**: BioHive-2 supercomputer – the largest in the pharmaceutical industry – enables rapid training and iteration on the World Model.
- **Bilingual Teams**: Recruitment of scientists and technologists fluent in both biology and AI, enabling tight integration across the platform.
- **Speed & Cost**: Demonstrated 3× faster discovery from hit identification to IND-enabling studies vs. traditional pharma averages, and reduced failure rates.
- **Open-Science Commitment**: Releases foundational models and datasets to accelerate the entire field while keeping the majority of proprietary data as a moat.

## Strategic Focus
- **Advancing Clinical Pipeline**: Prioritize oncology and rare disease programs, with several Phase 1/2 trials underway (e.g., TUPELO trial for REC-4881 in FAP).
- **Deepen Partnerships**: Expand therapeutic co-development deals and technology collaborations with NVIDIA, Google Cloud, and others.
- **Platform Enhancement**: Continue scaling the Recursion OS through more data, better models, and increased compute; open-source key components to attract top talent and drive innovation.
- **Global Expansion**: Grow hubs in Salt Lake City, London, Toronto, and Montreal to access diverse talent pools.

## Why Work Here
- **Culture**: Recursion prioritizes belonging, collaboration, and career development. Employee resource groups (PRIDE, Women, BIPOC) and regular social/community events foster inclusion.
- **Work Policy**: Hybrid/remote flexibility – some roles (e.g., VP Head of Clinical Operations) are fully remote, while others are based in Salt Lake City, London, Toronto, or Montreal.
- **Benefits**: Exceptional healthcare (including mental health), equity, bonuses, paid professional development (Coursera, coaching), and a strong emphasis on work-life balance.
- **Engineering & Science Culture**: Work alongside “bilingual” teams of AI researchers, chemists, biologists, and engineers on a mission to solve massive biological challenges. Access to one of the world’s most powerful supercomputers and cutting-edge automated labs.

## Sources
1. [Recursion.com – Overview & Technology](https://www.recursion.com/)
2. [Recursion.com – Careers](https://www.recursion.com/careers)
3. [Recursion.com – FAQ](https://www.recursion.com/faq)
4. [Recursion.com – Our Story](https://www.recursion.com/our-story)

## Other roles at Recursion

- [Vice President, Business Development and Licensing](https://feeny.ai/job/vice-president-business-development-and-licensing-recursion-new-york-g7fmffvyz3q0) — New York, NY
- [Director, Clinical Pharmacology](https://feeny.ai/job/director-clinical-pharmacology-recursion-new-york-m3cqa6yhnjmx) — New York, NY / Salt Lake City, UT
- [Director, Clinical Pharmacology](https://feeny.ai/job/director-clinical-pharmacology-recursion-london-yyy2pndcdy2r) — London, United Kingdom
- [Director, Regulatory Affairs](https://feeny.ai/job/director-regulatory-affairs-recursion-london-vx7mazxzrb4y) — London, United Kingdom / United Kingdom
- [Executive Director, Asset Strategy Leadership](https://feeny.ai/job/executive-director-asset-strategy-leadership-recursion-new-york-3swac2xhpqtt) — New York, NY
- [Engineering Manager - Machine Learning](https://feeny.ai/job/engineering-manager-machine-learning-recursion-canada-toronto-canada-84vktbzqj77z) — Canada / Toronto, Canada
- [Director, Regulatory Affairs](https://feeny.ai/job/director-regulatory-affairs-recursion-new-york-gdg6j1a9r7vp) — New York, NY / United Kingdom / United States / Salt Lake City, UT
- [Senior Computational Biologist - Early Discovery Oncology](https://feeny.ai/job/senior-computational-biologist-early-discovery-oncology-recursion-new-york-ch3n8qvj3sj3) — New York, NY / Salt Lake City, UT
- [Executive Director, Corporate Strategy & Intelligence](https://feeny.ai/job/executive-director-corporate-strategy-intelligence-recursion-new-york-k9dz38n06q6b) — New York, NY
- [Associate Director, Computational Biology – Early Discovery](https://feeny.ai/job/associate-director-computational-biology-early-discovery-recursion-salt-lake-jd1d066n9q0s) — Salt Lake City, UT